Two recently-signed agreements will transfer Takeda’s measles and acellular pertussis vaccine technologies to India-based multinational company Biological E. Limited to develop low-cost combination vaccines including diphtheria, tetanus and acellular pertussis (DTaP), and measles-rubella (MR) vaccines.
A loan from the European Investment Bank will give BiondVax resources for Phase III trials and a manufacturing facility for its universal flu vaccine.
The company successfully produced cell-based influenza vaccines at a commercial scale in its facility in NC.
The agency issued its recommendation for the influenza virus strains European vaccine manufacturers should include for 2017.
In a new study, researchers from Boston Children’s Hospital study responses to pneumococcal vaccine in infant monkeys.
Prokarium in the UK and Probiomed in Mexico hope to demonstrate large-scale production of oral vaccines that will reduce cost compared to injections and improve availability.
Emergent signed a follow-up contract to provide 29.4 million doses of BioThrax to the Strategic National Stockpile.
Univercells received a grant from the Bill & Melinda Gates Foundation for the development of a vaccine manufacturing platform.
GlaxoSmithKline opened a new vaccines R&D center in Rockville, MD creating up to 200 new jobs.
Takeda will invest more than 100 million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.
The company plans to expand access to its Prevanar 13 vaccine in humanitarian emergency settings.
Research by agency scientists may help speed development of Zika virus vaccines.
The study in 48 healthy adults will assess the safety and immunogenicity of a prime-boost regime of two different intranasal doses of the RSV vaccine, SynGem.
German biotech ARTES and Iranian biopharma manufacturer BioSun will develop an HPV vaccine.
Insulin has been shown to improve the production of viruses and viral vectors.
The companies will collaborate the manufacture of personalized cancer vaccines.
HHS entered into a contract with BioProtection Systems Corp. for commercial manufacturing tests of an Ebola vaccine.
The hospital received a five-year $5 million grant from CDC to survey for communicable diseases in children and evaluate vaccine effectiveness.
Zika vaccine development is hindered by technical challenges and funding shortfalls.
The Phase I trial will test Bavarian Nordic’s vaccine, which is manufactured using a vaccine vector based on smallpox.
The vaccine candidate has also won a Priority Medicines (PRIME) status from EMA.
The company will collaborate with the Walter Reed Army Institute of Research to co-develop a Zika vaccine candidate.
Two recently published studies suggest that pre-exposure to the dengue virus (DENV) could predict a person’s reaction to the Zika virus (ZIKV) because of of the antigenic similarity between the viruses. One study was published on June 23, 2016 in Nature Immunology and the other on June 27, 2016 in Proceedings of the National Academy of Sciences of the United States of America (PNAS). Dengue and Zika are both mosquito-borne flaviviruses that are cross-reactive.
MilliporeSigma and the International Vaccine Institute in Seoul, South Korea aim to develop more robust, scalable vaccine manufacturing processes.
Studying broadly neutralizing antibodies in infants may lead to new pathways in HIV vaccine development.
